KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Equity Ratio (2016 - 2025)

Rigel Pharmaceuticals has reported Equity Ratio over the past 16 years, most recently at 0.76 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 3701.35% year-over-year to 0.76; the TTM value through Dec 2025 reached 0.76, up 3701.35%, while the annual FY2025 figure was 0.76, 3701.35% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.76 at Rigel Pharmaceuticals, up from 0.48 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.76 in Q4 2025 and troughed at 0.28 in Q3 2023.
  • A 5-year average of 0.06 and a median of 0.0 in 2022 define the central range for Equity Ratio.
  • Biggest five-year swings in Equity Ratio: plummeted 735.86% in 2023 and later soared 3701.35% in 2025.
  • Year by year, Equity Ratio stood at 0.18 in 2021, then crashed by 155.86% to 0.1 in 2022, then plummeted by 140.97% to 0.24 in 2023, then soared by 108.21% to 0.02 in 2024, then soared by 3701.35% to 0.76 in 2025.
  • Business Quant data shows Equity Ratio for RIGL at 0.76 in Q4 2025, 0.48 in Q3 2025, and 0.4 in Q2 2025.